Ninety-five percent of GLP-1 users report eating smaller portions, and 87% are snacking less, and 81% are eating less frequentlysignaling a significant shift in eating habits among users
Accessed August 10
High purity (99%), suitable for controlled laboratory experiments
Commonly reported: temporary facial flushing, mild water retention in the first 1-2 weeks, vivid dreams, deeper sleep, and a small post-injection hunger bump from Ipamorelin
Maximizing GLP-1 dosing alone typically produces 15-24% weight loss, which is substantial
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors